NCT05749211View on ClinicalTrials.gov

Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Ovarian Cancer
Interventions
DRUG

Huaier granule

Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT05749211 - Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer | Biotech Hunter | Biotech Hunter